首页> 美国卫生研究院文献>BMC Cancer >Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

【2h】

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

机译：II期关于Nivolumab与Folfoxiri / Bevacizumab在晚期结直肠癌RAS或BRAF突变的患者中的一线治疗 - Nivacor试验（GOIRC-03-2018）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Clinical Trials in mCRC of immune-checkpoint inhibitors as single agents or in combination

机译：免疫检查点抑制剂MCRC的临床试验作为单一药剂或组合

著录项

期刊名称 BMC Cancer
作者
Angela Damato; Francesco Iachetta; Lorenzo Antonuzzo; Guglielmo Nasti; Francesca Bergamo; Roberto Bordonaro; Evaristo Maiello; Alberto Zaniboni; Giuseppe Tonini; Alessandra Romagnani; Annalisa Berselli; Nicola Normanno; Carmine Pinto;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

机译：转移性结肠直肠癌;第一线疗法;Nivolumab;folfoxiri bevacizumab;

相似文献

外文文献
中文文献
专利

1. Phase II study on first-line treatment of NIV olumab in combination with folfoxiri/bevacizumab in patients with Advanced CO lo R ectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) [J] . Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, BMC Cancer . 2020 ,第1期

机译：II期关于NIV Olumab与Folfoxiri / Bevacizumab在高级CO RO植物癌RAS或BRAF突变患者中的一线治疗 - NIVAC突变 - NIVACOR试验（GOIRC-03-2018）
2. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial [J] . Cremolini Chiara, Malmorino Federica, Bergamo Francesca, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019 ,第期

机译：第II期随机研究用Bevacizumab或Bevacizumab加上一流诱导叶昔昔昔单乳蛋白酶转移结直肠癌患者的牛伐单抗和贝伐单抗化疗研究：MOMA试验
3. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: A phase II trial by the Gruppo Oncologico Nord Ovest (GONO) [J] . FornaroL., LonardiS., MasiG., Annals of oncology: official journal of the European Society for Medical Oncology . 2013 ,第8期

机译：FOLFOXIRI联合帕尼单抗作为四联野生型（KRAS，NRAS，HRAS，BRAF）转移性结直肠癌患者的一线治疗：Gruppo Oncologico Nord Ovest（GONO）的II期试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer [O] . Masaaki Miyo, Takeshi Kato, Takayuki Yoshino, 2020

机译：Quattro-II研究的协议：多中心随机阶段II研究将Capoxiri加Bevacizumab与Folfoxiri加Bevacizumab相比作为转移结直肠癌患者的一线治疗
7. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study [O] . Eiji Oki, Takeshi Kato, Hideaki Bando, 2018

机译：Folfoxiri加Bevacizumab的多中心临床研究II研究作为转移性结肠直肠癌患者的一线治疗：Quattro研究

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

摘要

著录项

相似文献

相关主题

期刊订阅